Company Overview

Bloomios, Inc. is a U.S.-based company operating in the cannabinoid wellness, nutraceutical, and consumer packaged goods sectors. The company has focused on the development, manufacturing, and commercialization of products containing hemp-derived cannabinoids, particularly cannabidiol (CBD), as well as wellness-oriented consumer products. Bloomios has historically targeted both business-to-business and direct-to-consumer channels through formulation, white-label manufacturing, and branded product distribution. Public disclosures indicate that the company has also explored broader opportunities in health and wellness product commercialization and strategic acquisitions within adjacent consumer categories.

The company evolved through a series of restructurings and strategic shifts tied to the rapidly changing U.S. hemp and cannabinoid market following the 2018 Farm Bill legalization framework for industrial hemp. Bloomios has sought to differentiate itself through vertically integrated product development capabilities, manufacturing relationships, and emphasis on regulatory-compliant cannabinoid formulations. Public filings and market disclosures indicate that management has periodically adjusted the company’s operating focus in response to evolving consumer demand, regulatory uncertainty, and capital market conditions affecting smaller publicly traded wellness companies.

Business Operations

Bloomios generates revenue primarily through cannabinoid-based product manufacturing, formulation services, and branded wellness product sales. The company’s operations have included development and commercialization activities tied to hemp-derived ingredients, finished consumer products, and private-label manufacturing arrangements. Public filings reference activities involving tinctures, gummies, topicals, capsules, and other wellness-focused formulations. The company has also explored opportunities in nutraceuticals and broader health-oriented consumer goods categories. Data regarding current revenue concentration and operational scale is limited in recent public disclosures, and some operational details are inconclusive based on available public sources.

The company’s operational footprint has historically centered in the United States, with manufacturing and sourcing relationships tied to domestic hemp and wellness supply chains. Bloomios has disclosed relationships with third-party manufacturers and distribution partners rather than maintaining large-scale vertically integrated cultivation infrastructure. Public records also reference strategic interests in acquisitions and partnerships intended to expand product portfolios and distribution capabilities. Information regarding material joint ventures or internationally significant subsidiaries remains limited in publicly available filings.

Strategic Position & Investments

Bloomios has positioned itself around growth opportunities in cannabinoid wellness products and adjacent consumer health categories. Strategic initiatives disclosed in public filings and investor communications have included acquisition evaluations, expansion of branded product offerings, and efforts to strengthen distribution channels. The company has pursued opportunities tied to emerging wellness trends, including hemp-derived cannabinoids and nutraceutical formulations, while adapting to regulatory developments affecting the CBD market in the United States.

The company has also explored inorganic growth through acquisition activity and strategic investments intended to diversify operations and improve market positioning. Public disclosures reference efforts involving wellness brands and consumer-product expansion initiatives, although the scale and long-term financial impact of these activities remain difficult to independently verify due to limited recent operational disclosures. Bloomios operates in a competitive market characterized by fragmented participants, evolving regulatory oversight, and pressure on smaller issuers to achieve scale and consistent profitability.

Geographic Footprint

Bloomios is headquartered in the United States and primarily operates within the domestic U.S. market. Its activities have centered on product development, distribution, and commercialization within the American cannabinoid and wellness sectors. Publicly available information indicates that the company’s supply chain and manufacturing relationships are also predominantly U.S.-based.

While Bloomios has referenced broader market opportunities beyond the United States, there is limited verifiable evidence of a substantial operational footprint across Europe, Asia-Pacific, or other international regions. Available public filings and disclosures suggest that the company’s principal commercial exposure remains concentrated in North America. Data regarding material international investments or operational influence is inconclusive based on available public sources.

Leadership & Governance

Bloomios is governed by an executive management team and board structure typical of smaller publicly traded companies. Leadership has emphasized strategic flexibility, acquisition-driven growth opportunities, and positioning within emerging wellness and cannabinoid consumer markets. Public company disclosures indicate a focus on navigating regulatory developments while seeking scalable commercial opportunities in health-oriented consumer products.

Key executives and leadership figures identified in public filings and corporate disclosures include:

• Michael Hill – Chief Executive Officer
• Brian Wagner – Chief Financial Officer

Additional executive and governance details may vary across reporting periods, and some leadership information is inconclusive based on available public sources and changes reflected in company filings.